First Kidney Transplant Trial Patient Treated
Released
Released
Announcement PDF
ASX ANNOUNCEMENT
12 December 2024
First Patient Treated With CYP-001 in Kidney Transplant Trial
Melbourne, Australia; 12 December 2024: Cynata Therapeutics Limited (ASX: “CYP”, “Cynata”, or the
“Company”), a clinical-stage biotechnology company specialising in cell therapeutics, has received
confirmation from its partner Leiden University Medical Centre (LUMC) that the first patient has been
treated with CYP-001 in the Phase 1/2 Nereid kidney transplant clinical trial.
CYP-001 is Cynata’s Cymerus™ iPSC 1-derived MSC 2 product candidate for intravenous use. The trial is
being funded and managed by LUMC, under the supervision of Prof Ton Rabelink 3 and Dr Siebe Spijker, 4
while Cynata will supply CYP-001 for use in the trial. Importantly, Cynata will retain full commercial rights
for this indication.
The primary objective of the trial is to study the safety and efficacy of CYP-001 – to determine if
administering MSCs after kidney transplantation allows patients to take a reduced amount of the
immunosuppressant drug tacrolimus, which is used to prevent the rejection of transplanted organs.
Although tacrolimus is effective at preventing rejection of transplanted kidneys, it is associated with
significant toxicity, including increased risk of serious infections, cancer, diabetes, and kidney
damage.5,6 Consequently, there is an urgent need to identify and evaluate safer methods of preventing
organ transplant rejection. If it can be demonstrated that Cymerus™ MSC-based therapy allows patients
to stop taking tacrolimus, or reduce tacrolimus dosage, this would be expected to reduce the level of
toxicity that they experience. Close to one hundred thousand kidney transplants are performed
worldwide every year.7
The trial will seek to recruit a total of up to 16 patients who have undergone a kidney transplant. The first
six patients will receive either one (n=3) or two (n=3) infusions of CYP-001, in addition to standard
treatment. Subject to favourable safety review of the initial cohorts, a further ten patients will receive two
infusions of CYP-001, followed by tacrolimus dose reduction.
Prof Rabelink and colleagues have previously published encouraging data from a clinical trial in which
MSCs derived from bone marrow were used in a similar way. They found that early tacrolimus withdrawal
with MSC therapy was safe, without increased rejection, and concluded that this is a potentially useful
approach after kidney transplantation. 8
Dr Spijker said:
“One of the most useful properties of MSCs is that they can instruct the immune system to slow down,
and tell it not to attack the new kidney as aggressively. This could allow patients to take less rejection
medication to preserve the kidney, or potentially even stop taking rejection medication completely. Our
previous studies involved MSCs derived from bone marrow, which is quite a tedious procedure, and one
that produces just a limited amount of MSCs. In contrast, Cynata’s iPSC-based platform allows
production of an effectively limitless supply of MSCs from one cell bank. We look forward to evaluating
these cells in this exciting study.”
Dr Kilian Kelly, Cynata’s Chief Executive Officer and Managing Director, said:
“This trial will help build the growing body of data on the use of Cymerus™ iPSC-derived MSCs in a wide
range of clinical indications. There are clear parallels between use of CYP-001 in kidney transplant
recipients, and use of CYP-001 in graft versus host disease, which led to very promising safety and
efficacy outcomes in a completed Phase 1 clinical trial. 9,10 We look forward to continuing to work with
Prof Rabelink, Dr Spijker and the wider team at LUMC on this important project.”
Cynata Therapeutics Limited
ABN – 98 104 037 372
Level 3, 100 Cubitt Street
Cremorne
VIC 3121
Australia
T: +613 7067 6940
E: info@cynata.com
www.cynata.com
-ENDSAuthorised for release by Dr Kilian Kelly, CEO & Managing Director
CONTACTS:
Dr Kilian Kelly, CEO & MD, Cynata Therapeutics, +61 (03) 7067 6940, kilian.kelly@cynata.com
Lauren Nowak, Media Contact, +61 (0)400 434 299, lauren@littlebigdeal.au
About Cynata Therapeutics (ASX: CYP)
Cynata Therapeutics Limited (ASX: CYP) is an Australian clinical-stage stem cell and regenerative medicine
company focused on the development of therapies based on Cymerus™, a proprietary therapeutic stem cell
platform technology. Cymerus™ overcomes the challenges of other production methods by using induced
pluripotent stem cells (iPSCs) and a precursor cell known as mesenchymoangioblast (MCA) to achieve economic
manufacture of cell therapy products, including mesenchymal stem cells (MSCs), at commercial scale without the
limitation of multiple donors.
Cynata has demonstrated positive safety and efficacy data for its Cymerus™ product candidates CYP-001 and CYP006TK, in Phase 1 clinical trials in steroid-resistant acute graft versus host disease (GvHD), and diabetic foot ulcers
(DFU), respectively. Further clinical trials are now ongoing: a Phase 2 trial of CYP-001 in GvHD under a cleared US
FDA IND; a Phase 1/2 trial of CYP-001 in patients undergoing kidney transplant; and a Phase 3 trial of CYP-004 in
osteoarthritis. In addition, Cynata has demonstrated utility of its Cymerus™ technology in preclinical models of
numerous other diseases, including critical limb ischaemia, idiopathic pulmonary fibrosis, asthma, heart attack,
sepsis, acute respiratory distress syndrome (ARDS) and cytokine release syndrome.
Cynata Therapeutics encourages all current investors to go paperless by registering their details with the
designated registry service provider, Automic Group.
iPSC = induced pluripotent stem cell.
MSC = mesenchymal stem (or stromal) cell.
3
Professor of Internal Medicine and Head of the Division of Nephrology and the Department of Internal Medicine at LUMC.
4
Internist-nephrologist at LUMC.
5
Schagen MR, et al. Expert Opinion on Drug Metabolism & Toxicology. 2023;19(7), 429-445.
6
Rodríguez‐Perálvarez M, et al. Am J Transplant. 2022 Mar 31;22(6):1671-1682.
7
Word Health Organization Global Database on Donation and Transplantation.
8
Reinders MEJ, et al. Am J Transplant. 2021;21:3055-3065.
9
Bloor AJC, et al. Nat Med. 2020;26:1720-1725.
10
Kelly K, et al. Nat Med. 2024;30(6):1556-1558.
1
2
Cynata Therapeutics Limited
ABN – 98 104 037 372
Level 3, 100 Cubitt Street
Cremorne
VIC 3121
Australia
T: +613 7067 6940
E: info@cynata.com
www.cynata.com
Share your feedback
Discover